pharmaceutical · input
GLP-1/GIP Dual-Agonist Peptide API (Tirzepatide)
Active pharmaceutical ingredient for tirzepatide (Mounjaro / Zepbound) — Eli Lilly's dual GIP/GLP-1 receptor agonist and the category-leading GLP-1 molecule by 2026 prescriptions. Like Novo's semaglutide it is a patent-protected molecule with a single authorized maker; Lilly's tirzepatide API/manufacturing is US-dominant with Irish capacity.
2
Source countries
0
Companies
1
Goods affected
0
Claims on record
What depends on it
Goods that need this input
1 essential American goods rely on glp-1/gip dual-agonist peptide api (tirzepatide) somewhere upstream in their supply chain.
Where it comes from
Source countries
Share of global supply, by country.
| Country | Share of supply |
|---|---|
| USUnited States of America | 85% |
| IEIreland | 15% |